重组人脑钠肽联合达格列净治疗射血分数降低的心力衰竭的效果  

Effect of recombinant human brain natriuretic peptide combined with Dapagliflozin on heart failure with reduced ejection fraction

作　　者：王俊 荣惠 郑俊良 汤建武 WANG Jun;RONG Hui;ZHENG Junliang;TANG Jianwu(Department of Cardiovascular,Pingxiang Mining Group Co.,Ltd.General Hospital,Jiangxi Province,Pingxiang337000,China)

机构地区：[1]萍乡矿业集团有限责任公司总医院心血管内科,江西萍乡337000

出　　处：《中国当代医药》2025年第10期65-68,共4页China Modern Medicine

基　　金：江西省卫生健康委科技计划项目(SKJP220228460)。

摘　　要：目的探讨重组人脑钠肽(hBNP)联合达格列净治疗射血分数降低的心力衰竭(HFrEF)的效果。方法选取2022年1月至2024年1月萍乡矿业集团有限责任公司总医院收治的81例HFrEF患者作为研究对象,采用抽签法将其分为对照组(40例)和观察组(41例)。对照组给予hBNP静脉泵入,观察组在此基础上增加口服达格列净。比较两组患者治疗效果、治疗前后的心室重构、心功能指标以及不良反应发生率。结果治疗5个月后,观察组的总有效率高于对照组,左室收缩末期内径、左室舒张末期内径低于对照组,左室射血分数(LVEF)高于对照组,血清N末端脑钠肽前体(NT-proBNP)低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论HFrEF患者采用hBNP联合达格列净治疗可以提高治疗效果,改善心功能和促进心肌细胞重新构建,且具有一定安全性。Objective To investigate the effect of recombinant human brain natriuretic peptide(hBNP)combined with Dapagliflozin in the treatment of heart failure with reduced ejection fraction(HFrEF).Methods A total of 81 patients with HFrEF in Pingxiang Mining Group Co.,Ltd.General Hospital from January 2022 to January 2024 were selected as the research objects,and they were divided into control group(40 cases)and observation group(41 cases)by drawing lots method.The control group was given hBNP intravenously pumped,and the observation group was additionally given Dapagliflozin orally.The therapeutic effect,ventricular remodeling,cardiac function indexes and the incidence of adverse reactions were compared between the two groups.Results After 5 months of treatment,the total effective rate of the observation group was higher than that of the control group,the left ventricular end-systolic diameter and left ventricular end-diastolic diameter were lower than those of the control group,the left ventricular ejection fraction(LVEF)was higher than that of the control group,and the serum N-terminal pro-brain natriuretic peptide(NT-proBNP)was lower than that of the control group,with statistical significances(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion hBNP combined with Dapagliflozin in HFrEF patients can improve the therapeutic effect,improve cardiac function and promote the reconstruction of cardiomyocytes,and has certain safety.

关 键 词：重组人脑钠肽 达格列净 心力衰竭 心室重构 

分 类 号：R541.6[医药卫生—心血管疾病]